Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss from Wegovy is almost always temporary. Most people who notice thinning while taking semaglutide find that shedding slows and regrowth begins within a few months, typically as the body adjusts to rapid weight loss rather than to the medicine itself. It is a real side effect, and it deserves a straight answer — which is why this page covers what causes it, when to expect recovery, and the small number of situations where it is worth talking to a doctor. Wegovy (semaglutide) is a prescription-only weight-management medicine assessed and prescribed by a clinician; a prescriber will always discuss side effects, including this one, as part of the process.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
When people first notice clumps in the shower or more hair on the brush, the natural assumption is that the injection is causing direct damage. This is understandable, but the evidence points elsewhere. The NHS medicines guidance on semaglutide lists hair loss among the reported side effects, but the mechanism behind it is almost certainly telogen effluvium rather than follicle toxicity.
Telogen effluvium is the scalp's response to sudden physical stress, crash diets triggered it long before GLP-1 medicines existed. When the body loses weight quickly, a higher-than-normal proportion of hair follicles pause their growth cycle and enter a resting phase. Around two to four months later, those resting hairs shed simultaneously. It looks alarming; it is not permanent damage.
For most Wegovy users, the shedding is modest, diffuse across the scalp rather than patchy, and self-limiting. Because the root cause is the metabolic shift, not semaglutide pharmacology, slowing or stopping the medicine does not always prevent it, the thinning may still follow a significant weight change. Stopping treatment is rarely the answer, and certainly not a decision to make without talking to the prescriber first. Our dedicated page on Wegovy hair loss covers the causes, patterns and what to expect in detail. A detailed look at patterns across patients is also available on our Wegovy side effects overview.
Recovery tends to follow a predictable arc. Shedding usually peaks somewhere between the third and sixth month of treatment, then trails off as the body settles at a new, more stable weight. Regrowth begins quietly (short, fine hairs at the hairline or temples are often the first sign) and full recovery can take another six to twelve months. For a closer look at what the timeline actually looks like, the recovery timeline after Wegovy page goes through it in more detail.
There is no clinically proven intervention that dramatically shortens this cycle, but nutritional status matters. Protein intake is the one factor most consistently flagged by clinicians: semaglutide suppresses appetite strongly, and people eating significantly less may not reach the protein levels that support normal hair turnover. Aiming for adequate protein at each meal (a practical goal to discuss with a dietitian or your prescriber) is the most evidence-consistent step you can take.
Iron deficiency is another common culprit in significant weight-loss contexts. A blood test from your GP can rule it out, and treating a deficiency, where present, tends to help hair recovery noticeably. Biotin supplements are widely marketed; the evidence for them in people without a biotin deficiency (rare) is thin. Save the money, prioritise protein and iron, and give time its due.
Telogen effluvium is benign. But not all hair loss during Wegovy treatment has the same cause, and a few patterns warrant a proper assessment rather than watchful waiting.
See your GP promptly if: the shedding is heavy and shows no signs of slowing after six months; you notice patchy loss rather than diffuse thinning; there is redness, scaling or itching at the scalp; or you feel generally unwell, unusually cold, or fatigued beyond what weight loss would explain (thyroid function is worth checking). These features point to conditions unrelated to Wegovy that coincidentally surfaced during treatment.
The MHRA's Yellow Card reporting system exists precisely for situations like this, if you believe Wegovy has contributed to a side effect, reporting it contributes to the national safety picture. You do not need certainty to file a report, only a reasonable suspicion. Our guide to Wegovy's reported side effects covers the full range, including the gastrointestinal effects that affect far more people than hair changes do.
If you are considering starting Wegovy and this concern is on your mind, it is exactly the kind of question our prescribers address during the consultation, not an afterthought, but part of understanding whether the treatment fits your situation. We also know that timing matters: whether you are planning to start before a holiday or simply want things sorted before the month turns, how Wegovy prescriptions work at an online pharmacy explains the process clearly. You can speak to our prescribers about suitability and side effects as part of a free consultation, no obligation, just a straight clinical conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.